Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss

Cancer Research

Volumn 65, Issue 1, 2005, Pages 277-283

  Smith, Helen J ^a   Mukerji, Pradip ^b   Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLBUTYRIC ACID; 3 HYDROXYBUTYRIC ACID; CHYMOTRYPSIN; ICOSAPENTAENOIC ACID; LEUCINE; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CANCER PATIENT; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; LEAN BODY WEIGHT; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SKELETAL MUSCLE; TUMOR GROWTH;

ANIMALS; BODY WEIGHT; EICOSAPENTAENOIC ACID; HUMANS; KINETICS; MICE; MUSCLE, SKELETAL; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PROTEASOME ENDOPEPTIDASE COMPLEX; VALERATES; WASTING SYNDROME; WEIGHT LOSS;

EID: 11244259394     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. De Wys WD. Weight loss and nutritional abnormalities in cancer patients: Incidence, severity and significance. In: Calman KC, Fearon KCH, editors. Clinics in oncology. Vol. 5. London: W.B. Saunders; 1986. p. 115-26.
2. Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992;51:251-65.
3. Windsor JA, Hill GL. Risk factors for postoperative pneumonia. The importance of protein depletion, Ann Surg 1998;208:209-17.
4. Evans WK, Makuch R, Clamon GH, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985;45:3347-53.
5. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
6. Simons JPFHA, Schols AMJ, Hoefnagels JMJ, Westerterp KR, ten Velde GPM, Wouters EFM. Effects of medroxyprogesterone acetate on food intake, body composition and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer. Cancer 1998;82:553-60.
7. Lundholm K, Bylund AC, Holm J, Schersten T, Skeletal muscle metabolism in patients with malignant tumour. Eur J Cancer 1976;12:465-73.
8. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol 2001;280:R1518-23.
9. Williams A, Sun X, Fischer JE, Hasselgren P-O. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999;126:744-50.
10. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001;61:3604-9.
11. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:S27-30.
12. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-6.
13. Nissen SL, Abumrad NN. Nutritional role of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB). J Nutr Biochem 1997;8:300-11.
14. Nissen S, Sharp R, May M, et al. Effect of leucine metabolite β-hydroxy-β-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996;81:2095-104.
15. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine and glutamine. Am J Surg 2002;183:471-9.
16. Bibby MC, Double JA, Ali SA, Fearon KCH, Brennan BA, Tisdale MJ. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 1987;78:539-46.
17. Mulligan HD, Mahony SM, Ross JA, Tisdale MJ. Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-α or interleukin-6. Cancer Lett 1992;65:239-43.
18. Kanayama H, Tanaka K, Aki M, et al. Changes in expression of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991;541:6677-85.
19. Shimbara N, Orino E, Sone S, et al. Regulation of gene expression of proteasome (multi-protease complexes) during growth and differentiation of human hematopoietic cells. J Biol Chem 1992;267:18100-9.
20. 2-glycoprotein. Biochim Biophys Acta 2004;1636:59-68.
21. Waalkes TP, Udenfriend SA. A fluorimetric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med 1957;50:733-6.
22. Orino E, Tanaka K, Tamura T, Sone S, Ogura T, Ichihara A. ATP-dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubiquitinated proteins in human HL-60 cells. FEBS Lett 1991;284:206-10.
23. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089-93.
24. 12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 1999;59:5507-13.
25. Yoshizawa F. Regulation of protein synthesis by branched-chain amino acids in vivo. Biochem Biophys Res Common 2004;313:417-22.
26. Panton LB, Rathmacher JA, Baier S, Nissen S. Nutritional supplementation of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) during resistance training. Nutrition 2000;16:734-9.
27. Lowell BB, Ruderman WB, Goodman MN. Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. Biochem J 1986;234:237-40.
28. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999;129:227-37S.
29. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001;233:9-17.
30. Bodine SC, Latres E, Baumheuter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
31. Temparis S, Asensi M, Taillandier D, et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 1994;54:5568-73.
32. Smith HJ, Wyke SM, Tisdale MJ. Mechanism of the attenuation of proteolysis-inducing factor (PIF) stimulated protein degradation in muscle by β-hydroxy-β-methylbutyrate (HMB). Cancer Res. In press 2004.
33. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using β-hydroxy-β- methylbutyrate, glutamine and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr 2000;24:133-9.
34. Rathmacher JA, Nissen S, Panton L, et al. Supplementation with a combination of β-hydroxy-β-methylbutyrate (HMB), arginine and glutamine is safe and could improve hematological parameters. JPEN J Parenter Enteral Nutr 2004;28:66-75.